Vibecotamab

MDS

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

314 Active assets in the MDS cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 4	BB
Anti-Thymoglobulin, Rabbit Peking University First Hospital	Phase 2/3	BB
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University	Phase 4	BB
FILGRASTIM City of Hope Medical Center	Phase 4	BB
Daunorubicin OHSU Knight Cancer Institute	Phase 3	BB

View all 50 →

Same molecule, other indications

Vibecotamab is also rated in:

acute myeloid leukemiaDormant

CCC

Indicative ·

54 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

CC

Indicative ·

47 / 100

CD4+/CD56+ hematodermic neoplasmDormant

CC

Indicative ·

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.